Article Text


Endometrial Adenocarcinoma With Pulmonary Recurrence
  1. Manoj P Rai1,
  2. Mandeep Singh Randhawa2,
  3. Divyesh Reddy Nemakayala1,
  4. Edwin B Marinas3
  1. 1Internal Medicine, Michigan State University / Sparrow Hospital, Lansing, Michigan, United States of America
  2. 2Department of Cardiology, Michigan State University/Sparrow Hospital, Lansing, Michigan, USA
  3. 3Department of Pathology, Sparrow Health System, Lansing, Michigan, USA
  1. Correspondence to Dr Manoj P Rai, manoj.rai{at}

Statistics from


We present the case of an 83-year-old woman with a history of grade 1 stage IB endometrial cancer (endometrial adenocarcinoma) (figure 1) involving the lower uterine segment. She underwent robotic hysterectomy with right salpingo-oophorectomy followed by brachytherapy. A year and a half later, she presented with difficulty in breathing. A chest X-ray showed 8 mm nodular density in the right lower lobe. The above finding was confirmed with CT. Given the concern for a malignant lesion, positron emission tomography/CT scan was performed, which revealed two metabolically active lung nodules, measuring 1.2 cm in the right middle lobe and other in the right lower lobe measuring 1.2 cm (figure 2). Video-assisted thoracoscopic wedge resection of the right lower lobe lung nodule was performed. The frozen section and histopathology revealed papillary adenocarcinoma (figures 3 and 4); nuclear staining was positive for oestrogen receptors and negative for thyroid transcription factor-1 (figure 5). Thus, primary lung adenocarcinoma was ruled out and diagnosis of metastatic endometrial carcinoma was established. She was then started on systemic chemotherapy with carboplatin and paclitaxel. The incidence of lung metastasis in patients with endometrial cancer is 2.34.6%.1 Patients with stage IVB endometrial carcinoma and deep myometrial invasion are at increased risk for lung metastasis.2 The risk factor associated with lung metastasis in our patient was the deep myometrial invasion.3 Surgical resection followed by systemic chemotherapy is the standard of care. Overall survival in patients with isolated pulmonary metastasis was 54 months as opposed to 10 months in patients with synchronised pulmonary recurrence (metastasis to other organs as well).2

Figure 1

Histopathology showing primary endometrial adenocarcinoma at the time of its diagnosis.

Figure 2

Positron emission tomography/CT showing two metabolically active lung nodules, measuring 1.2 cm in the right middle lobe and other in the right lower lobe measuring 1.2 cm.

Figure 3

Frozen section showing papillary adenocarcinoma.

Figure 4

Final pathology showing metastatic endometrial carcinoma in the lung.

Figure 5

Slide shows positive nuclear staining for oestrogen receptor and negative nuclear staining for thyroid transcription factor-1.

Learning points

  • Endometrial cancer in stage IB has the propensity to recur even after surgical excision and brachytherapy.

  • Solitary lung lesion in a patient with previously treated endometrial carcinoma should be biopsied to rule out pulmonary metastasis.

  • Positive nuclear staining for oestrogen receptors and negative nuclear staining for thyroid transcription factor-1 can differentiate primary lung adenocarcinoma from endometrial carcinoma.

  • Patients with isolated pulmonary metastasis have an overall survival of 54 months.


View Abstract


  • MSR and DRN contributed equally.

  • Contributors MPR contributed to the manuscript (case description and learning points). MSR assisted with writing case description. DRN revised the manuscript. EBM provided description on the pathology slides.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.